Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Frequently asked questions
What sector does Tenaya Therapeutics Inc (TNYA) operate in?
Tenaya Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Tenaya Therapeutics Inc (TNYA) current stock price?
As of the latest data, Tenaya Therapeutics Inc stock price is $0.73, with a previous close of $0.76. Tenaya Therapeutics Inc lost -$0.03 in the last trading session, representing a -3.99% loss.
What is Tenaya Therapeutics Inc (TNYA) current market capitalization?
Tenaya Therapeutics Inc market cap is approximately 164.36 million.
What is Tenaya Therapeutics Inc (TNYA) Earnings Per Share (EPS)?
The trailing EPS is -$0.41, and the forward EPS is -$0.43.
What is Tenaya Therapeutics Inc (TNYA) EBITDA?
Tenaya Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -41.70 million.
Does Tenaya Therapeutics Inc (TNYA) pay dividends?
No. Tenaya Therapeutics Inc does not pay a dividend.
How did Tenaya Therapeutics Inc (TNYA) perform in its most recent earnings report?
In the last report (June 30, 2026), Tenaya Therapeutics Inc posted an EPS surprise of -12.5% and a revenue surprise of -88.9%.
What is Tenaya Therapeutics Inc (TNYA) beta (volatility) score?
Tenaya Therapeutics Inc has a beta of 2.791, indicating very high volatility compared to the market.
